INVESTOR NOTICE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

A class action lawsuit has been filed against Erasca, Inc. alleging that the company and its executives made false and misleading statements regarding its ERAS-0015 drug candidate. The lawsuit claims preclinical data was based on improper comparisons to Revolution Medicines and lacked reasonable basis. Following disclosure of a patent infringement letter from Revolution Medicines and adverse Phase I clinical data including a patient death, Erasca's stock fell approximately 59% in total.